BLICKENSTAFF KIM D, Executive Chairman, subtracted 200,000 shares of Tandem Diabetes Care, Inc. (TNDM) from its portfolio at the rate of $59.85 per share valuing $11,970,491 on Dec 16. The insider left behind 691,750 shares of the company to its portfolio. Currently, the 1st Resistance Point for this stock is $68.27, with a 2nd Resistance Point sitting at $69.20. Meanwhile, this company’s stock has a 1st Support Level at $66.71 and a 2nd Support Level at $66.08. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Tandem Diabetes Care, Inc. (TNDM) was $67.35. Tandem Diabetes Care, Inc. (TNDM) stock has gained $5.98, or 9.74%, in the past five days. In the last full month, these shares have gained $6.59, or 10.85%. In the past three months, this stock’s price has risen by $10.73, or 18.95%. This year-to-date, Tandem Diabetes Care, Inc. (TNDM) shares have gained $7.74, or 12.98%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Tandem Diabetes Care, Inc. (TNDM) stock, 50% of short-term indicators suggest that these shares are a “ Buy .” Looking further ahead, 50% of long-term indicators suggest that this stock is a “ Buy .”
With 59,093 K shares outstanding, this company currently has a market capitalization of $4,013,005K. Tandem Diabetes Care, Inc. (TNDM) generates $183,870 K in annual sales, amounting to annual net income of -$122,610 K. This stock has generated a 1-Year Total Return of 63.39%, a 3-Year Total Return of 156.26%, and a 5-year Total Return of -47.56%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in 09/19, Tandem Diabetes Care, Inc. (TNDM) reported earnings of -$0.13 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.20 per share, representing a 0.07 difference and 35.00% surprise. In the previous quarter ending in 06/19, the reported earnings of -$0.03 represented a 0.20 difference from the consensus estimate calling for -$0.23 per share, which was a 86.96% surprise.
For the current fiscal quarter, which is set to end in 12/2019, the average earnings estimate is -$0.08 per share. This estimate came from a total of 7 Wall Street Analysts. Of those market experts, the high estimate was $0.06 and the low estimate was -$0.21. In the year-ago quarter, Tandem Diabetes Care, Inc. (TNDM) generated per-share earnings of $0.02. If the analysts are correct about the current quarter’s earnings, the growth will be -500.00%.
Turning our focus now to insider trading activity, there have been 4 purchases (35,462 shares in total) and 10 sale (235,462 shares in total) in the last 3 months. In the last 6 months, there have been 11 insider buys amounting to 77,386 shares and 30 insider sales amounting to 708,154 shares. In the past full year, 32 insider purchases were made (involving 260,920 shares) and 66 insider sell-offs equivalent to 1,195,159 shares.
Moving onto liquidity, Tandem Diabetes Care, Inc. (TNDM) has a Current Ratio of 2.83, a Quick Ratio of 2.53 and a Cash Ratio of 1.95. Looking even further ahead into the future, its Long-Term Debt to Equity is -5.88.